Baird analyst David Rescott lowered the firm’s price target on Medtronic (MDT) to $93 from $96 and keeps a Neutral rating on the shares. The firm said while FY25’s HSD EPS growth exit rate remains a positive out-year indicator, into FY26 the company will contend with ongoing FX pressures, dilutive new product/capital rollouts and a slight tax headwind which Baird thinks will limit a sustainable return to HSD EPS growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $98 from $106 at Wells Fargo
- Medtronic Reports Strong Q2 2025 Results, Raises Guidance
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Morning Movers: Walmart jumps following quarterly results
- MDT Earnings: Medtronic Beats Q2 Expectations, Boosts FY25 Guidance